Neoantigen therapy is a novel cancer therapy that targets tumor-specific antigens resulting from genetic mutations. The session "Neoantigen Therapy" explores how such specific antigens can be used to induce specific and efficient immune responses against cancer cells.".
Neoantigens are absent in non-malignant tissues, thus they are the best candidates for personalized immunotherapy, such as vaccines, T-cell therapy, and adoptive cell transfer. Through genomic sequencing and bioinformatics, clinicians are able to identify patient-specific neoantigens that can be used to create personalized therapies that engage the immune system to target and destroy cancer cells but not normal tissue.
The session discusses methods to maximize presentation of neoantigens, bypass immune suppression, and synergize therapies with checkpoint blockers or other immunomodulating therapies. Clinical trials have indicated encouraging outcomes, including regression of tumors, extended survival, and enhanced responses across cancer types.
Participants will learn about the biology of neoantigens, approaches to identification and validation, and therapeutic uses in individualized cancer therapy. This presentation highlights the revolutionary promise of neoantigen therapy to offer highly precise, immune-based treatments, moving precision oncology forward and providing new hope for patients with resistant or difficult cancers.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
